®

COMPREHENSIVE BIOMARKER TEST

TURN DEEP INSIGHTS INTO PERSONALIZED TREATMENT STRATEGIES OncoDEEP® is the most comprehensive biomarker test designed to help oncologists determine the best treatment(s) for their patients living with advanced solid tumors. Through the inclusion of the most up-to-date scientific insights and clinical evidence, OncoDEEP® spearheads comprehensive molecular profiling in oncology. This single assay is able to identify all biomarkers required for prescribing approved biomarker-associated therapies, as well as guiding choice of and highlighting potential clinical trial options. When selecting therapeutic options at diagnosis or after a first- ® IN A NUTSHELL line treatment failed, oncologists can rely on ONCODEEP ® OncoDEEP to provide a timely therapy that precisely matches their patient disease. Solid tumors (stage III or IV) 1 in adults and glioblastoma in children Used at diagnosis or at disease progression Used for extra therapeutic guidance • Standard of care have been exhausted • Biomarkers identified are not useful • Highly aggressive or rare cancers 638 FFPE tissue < 2weeks

In less than two weeks, OncoDEEP® generates a comprehensive report that contains deep insights into a patient’s tumor profile as well as therapeutic options, such as chemotherapy, immunotherapy, and hormone therapy; and potential clinical trial options.

1 RECOMMENDED USE, AT DIAGNOSIS:

Comprehensive profiling is recommended at diagnosis for patients with advanced cancer where biomarker-matched targeted therapies are available. Comprehensive profiling using a single assay has a number of advantages over iterative single biomarker testing: use of a single assay is often cheaper than deploying multiple single assays, yields faster results and is less likely to exhaust biopsy material. OncoDEEP® WILL HELP YOU TO:

» Identify approved treatments likely to be effective for your patient; » Define which types of therapies your patient is resistant to; » Consider appropriate clinical trials; » Understand why a treatment stopped working.

In less than two weeks, OncoDEEP® generates a comprehensive report that contains deep insights into a patient’s tumor profile as well as therapeutic options, such as chemotherapy, immunotherapy, targeted therapy and hormone therapy; and potential clinical trial options.

1 RECOMMENDED USE, AT DISEASE PROGRESSION:

When asked, the vast majority of those living with cancer express their willingness to participate in a clinical trial; however, only a small minority are able to make this a reality. This is despite a growing body of opinion supporting access to clinical trials as part of the routine care pathway. Importantly, close to 40% of oncology clinical trials use biomarker stratification to assign patients to therapy. Access to comprehensive molecular profiling provides patients and their physicians with the opportunity to consider all the available clinical trial options. Considering clinical trials early in the treatment pathway allows forward planning, enabling patients to find the most suitable trial available locally or at hospitals further afield. TARGETED COMBINATION OF BIOMARKERS TO IMPROVE CLINICAL BENEFITS

A study demonstrated the clinical utility of integrating DNA, RNA and in one single biomarker test. The trial was led on 1,057 advanced cancer patients in 30 countries (4 continents) that had already experienced treatment failure(s).

1. NGS ALONE IS NOT ENOUGH TO DECIDE FOR TREATMENT

8% 27% 92%

Patient without treatment

Patient with therapeutic of the oncologists believe 73% 92% alternative that combining NGS with cancer-specific 1 NGS only Protein biomarkers biomarkers provides better clinical insights . and NGS

2. ADOPTION OF OUR HOLISTIC APPROACH

4.2% 3.1% Treatment changed against our 92,7% recommendations

Treatment changed according & against our recommendations

Treatment unchanged according of the oncologists to our recommendations 32.3% acknowledged OncoDNA recommendations Treatment changed according were clinically relevant. 60.4% to our recommendations

3. IMPROVED OVERALL SURVIVAL2

Kaplan Meier Survival Analysis

100%

90%

80%

70% BASED ON ONCODNA APPROACH : 60% • At least 50% of the patients had an 50% overall survival of > 6 months. 40%

Percentage Survival • 27% of the patients had a minimum overall 30% 27 20% survival > 12 months (expected OS of 10% ~3 - 6 months) (Laes et al 2018) 365 0% 0 100 200 300 400 500 600 700 800 900 1000 1100

Number of days 1 Protein biomarkers of response to targeted therapies, immunotherapy, hormone therapy and chemotherapy.

2 The overall survival of patients was assessed for all cases where our therapeutical recommendations were applied (n=114) Combining different molecular profiling assaysis the key to maximize the clinical benefit of the treatment.

BASED ON ONCODNA APPROACH : • At least 50% of the patients had an overall survival of > 6 months. • 27% of the patients had a minimum overall survival > 12 months (expected OS of ~3 - 6 months) (Laes et al 2018) A UNIQUE COMBINATION OF LEADING-EDGE TESTS

Starting from a sample of tumor tissue, OncoDEEP® includes the screening of genomic alterations (DNA & RNA), genomic signatures (microsatellite instability, tumor mutational burden & homologous recombination deficiency) and protein biomarkers of response to targeted therapies, immunotherapy, hormone therapy and chemotherapy. OncoDEEP® is now more robust and more accurate than ever thanks to a technology switch to Illumina and Twist Bioscience.

MICROSATELLITE INSTABILITY (MSI)

• Inclusion of 1,650 sequences to increase the accuracy and SNVS, INDELS, CNV robustness of this biomarker

• SNPs in TSG regions to improve the analysis of Sensitivity prediction to targeted therapies & LOH or homozygous deletions immunotherapy

• SNPs in genes and sub-telomeric regions to assess the HRD phenotype

Sensitivity prediction to targeted therapies & immunotherapy

Better uniformity and genomic backbone TUMOR MUTATIONAL BURDEN (TMB) to improve the analysis of CNV or complex regions • 2.3Mb of genomic content to better address TMB in low mutational burden tumors

Sensitivity prediction to immunotherapy for TMB-high solid tumors HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) PHENOTYPE

OncoDEEP® provides a score based on algorithmic measurement of 2 tumor factors:

• Loss of heterozygosity (LOH) • Telomeric allelic imbalance (TAI)

Sensitivity prediction to PARP-inhibitors for HR-deficient tumor

MICROSATELLITE INSTABILITY (MSI)

• Inclusion of 1,650 sequences to increase the accuracy and robustness of this biomarker

Sensitivity prediction to targeted therapies & immunotherapy FUSION GENES & UNUSUAL SPLICING

• ALK • FGFR • ROS1 • NTRK • RET • METex14

Sensitivity prediction to targeted therapy

TUMOR MUTATIONAL BURDEN (TMB)

• 2.3Mb of genomic content to better address TMB in low mutational burden tumors

Sensitivity prediction to immunotherapy for TMB-high solid tumors COMPREHENSIVE PANEL

The OncoDEEP® gene panel contains a total of 638 genes that were carefully selected based on their biological and therapeutical relevance.

ABL1 BABAM1 CD79B CXCR4 EPHB1 FGF10 GEN1 HNRNPK ABL2 BAP1 CDC42 CYLD EPHB4 FGF12 GID4 HOXB13 ACVR1 BARD1 CDC73 CYP17A1 ERBB2 FGF14 GLI1 HRAS ACVR1B BBC3 CDH1 CYP19A1 ERBB3 FGF19 GNA11 HSD3B1 ADARB2 BCL10 CDH4 CYP2C19 ERBB4 FGF2 GNA13 HSP90AA1 AGO1 BCL2 CDK12 CYP2D6 ERCC1 FGF23 GNAQ ICOSLG AGO2 BCL2L1 CDK4 CYSLTR2 ERCC2 FGF3 GNAS ID3 AJUBA BCL2L11 CDK6 DAXX ERCC3 FGF4 GNB1 IDH1 AKT1 BCL2L2 CDK7 DCUN1D1 ERCC4 FGF5 GPR124 IDH2 AKT2 BCL6 CDK8 DDR1 ERCC5 FGF6 GPS2 IFNGR1 AKT3 BCOR CDKN1A DDR2 ERF FGF7 GREM1 IGF1 ALB BCORL1 CDKN1B DDX41 ERG FGF8 GRIN2A IGF1R ALK BCR CDKN2A DHX15 ERRFI1 FGF9 GRM3 IGF2 ALOX12B BIRC3 CDKN2B DICER1 ESR1 FGFR1 GSK3B IKBKE AMER1 BLM CDKN2C DIS3 ETAA1 FGFR2 H3F3A IKZF1 ANKRD11 BMPR1A CEBPA DNAJB1 ETS1 FGFR3 H3F3B IL10 ANKRD26 BRAF CENPA DNMT1 ETV1 FGFR4 H3F3C IL7R APC BRCA1 CHD2 DNMT3A ETV4 FH HDAC1 INHA APLNR BRCA2 CHD4 DNMT3B ETV5 FLCN HGF INHBA AR BRD4 CHEK1 DOT1L ETV6 FLI1 HIST1H1C INPP4A ARAF BRIP1 CHEK2 DPYD EWSR1 FLT1 HIST1H2BD INPP4B ARFRP1 BTG1 CIC DROSHA EZH1 FLT3 HIST1H3A INPPL1 ARHGAP35 BTG2 CMTR2 DUSP4 EZH2 FLT4 HIST1H3B INSR ARID1A BTK CNTN4 E2F3 EZR FOXA1 HIST1H3C IRF2 ARID1B CALR CREBBP EED FAM175A FOXF1 HIST1H3D IRF4 ARID2 CARD11 CRKL EGFL7 FAM46C FOXL2 HIST1H3E IRS1 ARID5B CARM1 CRLF2 EGFR FAM58A FOXO1 HIST1H3F IRS2 ASXL1 CASP8 CSDE1 EIF1AX FANCA FOXP1 HIST1H3G JAK1 ASXL2 CBFB CSF1R EIF4A2 FANCC FRS2 HIST1H3H JAK2 ATM CBL CSF3R EIF4E FANCD2 FUBP1 HIST1H3I JAK3 ATR CCNB3 CSNK1A1 ELF3 FANCE FYN HIST1H3J JUN ATRX CCND1 CTCF EML4 FANCF GAB1 HIST2H3A KAT6A ATXN7 CCND2 CTLA4 EMSY FANCG GAB2 HIST2H3C KBTBD4 AURKA CCND3 CTNNA1 EP300 FANCI GABRA6 HIST2H3D KDM5A AURKB CCNE1 CTNNB1 EPAS1 FANCL GATA1 HIST3H3 KDM5C AXIN1 CD276 CTR9 EPCAM FAS GATA2 HLA-A KDM6A AXIN2 CD70 CUL3 EPHA3 FAT1 GATA3 HLA-B KDR AXL CD74 CUL4A EPHA5 FBXW7 GATA4 HLA-C KEAP1 B2M CD79A CUX1 EPHA7 FGF1 GATA6 HNF1A KEL Panel size more than doubled

KIF5B MPL P2RY8 PPM1D RICTOR SMARCB1 TGFBR1 KIT MRE11A PAK1 PPP2R1A RIT1 SMARCD1 TGFBR2 KLF4 MSH2 PAK3 PPP2R2A RNF43 SMARCE1 TIPARP KLF5 MSH3 PAK7 PPP4R2 ROS1 SMC1A TMEM127 KLHL6 MSH6 PALB2 PPP6C RPS6KA4 SMC3 TMPRSS2 KMT2A MSI1 PARK2 PRDM1 RPS6KB1 SMO TNFAIP3 KMT2B MSI2 PARP1 PRDM14 RPS6KB2 SMYD3 TNFRSF14 KMT2C MST1 PARP2 PREX2 RPTOR SNCAIP TOP1 KMT2D MST1R PARP3 PRKAR1A RRAGC SNTG2 TOP2A KMT5A MTAP PAX3 PRKCI RRAS SOCS1 TP53 KNSTRN MTOR PAX5 PRKD1 RRAS2 SOS1 TP53BP1 KRAS MUTYH PAX7 PRKDC RSPO2 SOX10 TP63 LAMP1 MYB PAX8 PRSS8 RTEL1 SOX17 TPMT LATS1 MYC PBRM1 PTCH1 RUNX1 SOX2 TRAF2 LATS2 MYCL PD-1 PTEN RUNX1T1 SOX9 TRAF7 LMO1 MYCN PD-L1 PTP4A1 RXRA SPEN TRIP13 LRP1B MYD88 PD-L2 PTPN11 RYBP SPOP TSC1 LTK MYOD1 PDGFRA PTPRD SCG5 SPRED1 TSC2 LYN NAB2 PDGFRB PTPRN2 SDC4 SPRTN TSHR LZTR1 NADK PDK1 PTPRS SDHA SPTA1 TYRO3 MAD2L2 NBN PDPK1 PTPRT SDHAF2 SRC U2AF1 MAGI2 NCOA3 PGBD5 QKI SDHB SRSF2 UGT1A1 MALT1 NCOR1 PGR RAB35 SDHC STAG1 UPF1 MAP2K1 NEGR1 PHF6 RAC1 SDHD STAG2 USP8 MAP2K2 NF1 PHOX2B RAC2 SERPINB3 STAT3 VEGFA MAP2K4 NF2 PIGA RAD21 SERPINB4 STAT4 VHL MAP3K1 NFE2L2 PIK3C2B RAD50 SESN1 STAT5A VTCN1 MAP3K13 NFKBIA PIK3C2G RAD51 SESN2 STAT5B WHSC1 MAP3K14 NKX2-1 PIK3C3 RAD51B SESN3 STK11 WHSC1L1 MAP3K4 NKX3-1 PIK3CA RAD51C SETBP1 STK19 WISP3 MAPK1 NOTCH1 PIK3CB RAD51D SETD2 STK40 WT1 MAPK3 NOTCH2 PIK3CD RAD52 SETDB1 SUFU WWTR1 MAPKAP1 NOTCH3 PIK3CG RAD54L SF3B1 SUZ12 XIAP MAX NOTCH4 PIK3R1 RAF1 SGK1 SYK XPO1 MCL1 NPM1 PIK3R2 RANBP2 SH2B3 TAF1 XRCC2 MDC1 NRAS PIK3R3 RARA SH2D1A TAP1 YAP1 MDM2 NRG1 PIM1 RASA1 SHOC2 TAP2 YES1 MDM4 NSD1 PLCG2 RB1 SHQ1 TBX3 ZBTB2 MED12 NT5C2 PLK2 RBM10 SLC34A2 TCEB1 ZBTB7A MEF2B NTHL1 PMAIP1 RECQL SLFN11 TCF3 ZFHX3 MEN1 NTRK1 PMS1 RECQL4 SLIT2 TCF7L2 ZNF217 MET NTRK2 PMS2 REL SLX4 TEK ZNF703 MGA NTRK3 PNRC1 REST SMAD2 TERT ZNRF3 MITF NUF2 POLD1 RET SMAD3 TET1 ZRSR2 MLH1 NUP93 POLE RFWD2 SMAD4 TET2 MLLT1 NUTM1 POT1 RHEB SMARCA2 TFE3 MLLT3 OPCML PPARG RHOA SMARCA4 TFRC PERSONALIZATION OF ONCODEEP®

Based on the patient cancer type, we run additional tests on specific biomarkers associated to the latest approved therapies.

Non-small cell 1 All solid tumors lung cancer (NSCLC)

Tumor mutational burden (TMB) EGFR (exon 19, exon 20 and exon 21 alterations) , , , Dacominitib Microsatellite instability (MSI) and Pembrolizumab, ALK, RET, ROS1 rearrangements , , , , , and FGFR and NTRK rearrangements3 Pemigatinib, and Breast cancer BRAF V600E (HR+ and/or HER2+) + MET single nucleotide variants (SNVs) and ESR1 and ER expression indels that lead to METexon 14 skipping Exemestane, Letrozole, Anastrozole, Tamoxifen, Fulvestrant PD-L1 (22C3 and SP142) PIK3CA exon 7: C420R; exon 9: E542K; , Pembrolizumab, E545A, E545D [1635G>T only], E545G, RRM1 E545K, Q546E, Q546R; and exon 20: H1047L, Gemcitabine H1047R, H1047Y TS Alpelisib Pemetrexed ERBB2 alterations and HER2 expression TUBB3 , , , Docetaxel, Nab-paclitaxel, Vinorelbine and Ado- TS Capecitabine, Fluorouracil TOP2A (only for HER2+) Colorectal cancer Doxorubicin, Epirubicin PTEN and p4EBP1 expression (only for HER2-) KRAS (exons 2, 3, 4) and NRAS (exons 2, 3, 4) and BRCA1/2 BRAF V600E Olaparib + Cetuximab NTRK1/2/32 ERCC1 Larotrectinib, Entrectinib Oxaliplatin TOPO1 Irinotecan

*All biomarkers per cancer-type listed on this double page are 2 associated to a FDA-approved drug. NTRK1/2/3 Larotrectinib, Entrectinib Specific biomarkers are also analyzed for other cancer types than those listed on this double page – they may vary according to the clinical evidence per cancer-type. Triple negative Prostate cancer breast cancer

AR (expression and AR SNVs, ARv7 variant) PD-L1 (SP142) Abiraterone, , , Nab-paclitaxel, Atezolizumab and Darolutamide BRCA1/2 BRCA1/2 and HRD phenotype Talazoparib Olaparib, Rucaparib TLE3 TUBB3 Eribulin Cabazitaxel, Docetaxel TOP2A NTRK1/2/32 Doxorubicin, Epirubicin Larotrectinib, Entrectinib TS Fluorouracil, Capecitabine NTRK1/2/32 Larotrectinib, Entrectinib Pancreatic cancer

BRCA1/2 Urothelial carcinoma Olaparib hENT1 Gemcitabine PD-L1 (SP142) ERCC1 Atezolizumab Oxaliplatin FGFR and NTRK rearrangements3 TUBB3 Pemigatinib, Entrectinib and Larotrectinib Docetaxel, Paclitaxel RRM1 NTRK1/2/32 Gemcitabine Larotrectinib, Entrectinib ERCC1 Cisplatin

Ovarian cancer

: DNA/RNA : Protein

BRCA1/2 and HRD phenotype

Olaparib, Niraparib, Rucaparib 1Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) scores will be calculated for any OncoDEEP® ordered. NTRK1/2/32 2VENTANA pan-TRK CE IVD/US test will be used. The VENTANA pan-TRK Larotrectinib, Entrectinib (EPR17341) CE IVD/US Class I Assay is designed to detect C-terminal protein expression, which allows for the detection of TRK-fusion as well as wild-type protein expression. In any positive case, a fusion panel (Archer® FusionPlex Lung panel) will be performed to confirm the presence of the fusion gene. 3Fusion panel used is the Archer® FusionPlex Lung panel. The Archer® FusionPlex Lung panel is a targeted NGS test to detect EGFRvIII and MET exon 14 skipping events along with prominent ALK, BRAF, FGFRs, NRG1, NTRKs, RET, and ROS1 fusions. ONCODEEP® FOR CANCER OF UNKNOWN PRIMARY ORIGIN

Carcinomas of unknown primary origin (CUP) account for 3%–5% of newly diagnosed advanced malignancies, with chemotherapy as standard of care. By definition, patients diagnosed with CUP have metastatic disease, but the specific site of the primary cancer is unknown. Consequently, traditional treatment approaches, which rely on the site of origin being known, are often ineffective1 .

Next-generation sequencing has revealed genomic alterations that can be targeted in selected cases, suggesting that CUP represents a unique malignancy in which the genomic aberrations may be integral to the diagnosis. Recent trials focusing on tailored combination therapy matched to the genomic alterations in each cancer are providing new avenues of clinical investigation. (Cancer of Unknown Primary in the Molecular Era, Razelle Kurzrock, 2021)

ESMO guidelines followed by OncoDNA to decipher the cancer type 1

Colorectal and Merkel cell carcinoma

Lung, breast, thyroid, endometrial, cervical and pancreatic carcinoma Cholangiocarcinoma

Urothelial, ovarian and pancreatic cancer Cholangiocarcinoma

Hepatocellular, renal cell, prostate, squamous cell carcinoma

1 PMID: 26314775 OncoDEEP® WILL HELP YOU TO :

» Decipher the primary origin of the cancer by running a set of immunohistochemistry analyses based on ESMO guidelines;

» Select an approved or off-label treatment based on biomarkers;

» Reveal treatment alternatives;

» Identify patient eligibility to clinical trials.

In ~ 80% of the cases, OncoDEEP® helped identify a possible primary tumor and guided clinicians through

the best treatment options2.

2 https://www.annalsofoncology.org/article/S0923-7534(19)32379-8/fulltext ONCODEEP® REPORT

The OncoDEEP® report can be consulted online via our interactive platform OncoSHARE™ and downloaded in PDF format.

1 MEDICAL INFORMATION • Patient details • Clinical form & pathology

2 DRUGS • List of therapies associated with ₀ Potential clinical benefit ₀ Potential lack of clinical benefit 1 ₀ Unknown clinical benefit ₀ Toxicity • Trade names, therapeutic classes, official indications • Approval status for the type of cancer and for other indications • Drugs in development

4

3 COMPREHENSIVE SUMMARY • Simplified molecular pathway • Summary of all relevant biological and clinical information

4 VARIANTS DETECTION • Complete list of variants classified according 7 to their biological and therapeutical impact Cancer Type: Patient Name: Patient ID: Sample ID: Validated on: Non-Small Cell Lung Cancer Patient Name xxxxxxxxxx xxxxxxxxxx 7 may 2019

OncoDEEP Analysis Report

GENERAL INFORMATION

Birth Date: 1965-01-21 Sex: M Medical Doctor: Micheal Johnson

Pathologist: John Doe Tumor Cell: 50% Biopsy Date :3/25/19

Biopsy Site: Primary Tumor Site Primary Tumor Site: Lung Cancer Type: Non-Small Cell Lung Cancer

Clinical Diagnosis: SCLC, NSCLC-adeno, and NSCLC-SqCC

Histological Diagnosis:

REPORT RESULT SUMMARY

Drugs

5 with potential clinical benefit 28 with lack of clinical benefit 0 associated with toxicity 8 with potentialcpotentialc linical beneÞt Variants

4 Pathogenic 2 Likely Pathogenic 51 Variants of Uncertain Significance (VUS) 8 8 8 Biomarkers for therapy responses

Targeted therapies Chemotherapy

Therapy Likely response?response? BiomarkersBiomarkers Therapy Likely response? Biomarkers

AKT inhibitors YES PTEN STOPSTOP p.Y240* p.Y240* Antimicrotubule agent NO IHC - TUBB3 High expression EGFR TK inhibitors YES EGFR || p.E746_A750del EGFR TK inhibitors YES EGFR || p.T790M

Topoisomerase 2 TOP2A - Topoisomerase 2 YES TOP2A - Positive expression inhibitors Positive expression ALK - Negative NO ALK - Negative Expression NO Expression Seq - Fusion inhibitors Seq - Fusion Panel NO Panel NO

Hormone Therapy Immunotherapy

Therapy Likely response? Biomarkers Therapy Likely response? Biomarkers

PD-L1 inhibitor NO • PD-L1 - Neg. Expression 5 • MSI - Stable • CD8OTHER - Neg. Expression BIOMARKERS • Immunohistochemistry analyses for Biomarkers associated with potential resistance or toxicity Therapy Biomarkerschemotherapy and targeted therapy EGFR TK inhibitors MET CNV • Unusual splicing and methylation 2 3 • Translocations or fusions

FAKE REPORT DISCORDING INFORMATION POSSIBLE POSSIBLE INFORMATION DISCORDING REPORT FAKE • HRD

powered by OncoKDM v.1.28. www.oncokdm.com - www.oncodna.com

6 IMMUNOGRAM • The immunogram shows the potential response of each patient to immunotherapy

5 6 7 CLINICAL TRIALS • List of all clinical trials of interest that match the molecular profile of the patient

8 BIBLIOGRAPHY • List of all literature used in the report that is related to the patient’s molecular profile 8

HOW TO ORDER AN ONCODEEP® BIOMARKER TEST ?

™

1 LOG IN TO

OncoSHARE™ is a highly secured, easy-to-use and user-friendly platform through which you can order our solutions, get access to dynamic analysis reports and connect with other healthcare professionals and with our team of scientists. www.oncoshare.com 2 ORDERING OF A TEST Proceed to payment via credit card through OncoSHARE™ or via wire transfer. We will ship the appropriate sample collection to you.

3 SAMPLE COLLECTION Collect the biopsy and place it in the sample collection kit. Kindly generate a prepaid shipping label online (https://delivery.oncodna.com), print it and stick it on your package. Request a DHL pickup to send the kit back to OncoDNA.

4 SAMPLE ANALYSIS On arrival at OncoDNA facilities, the sample quality is checked and the sample is recorded in our tracking system for further analysis.

5 AVAILABILITY OF YOUR REPORT The analysis results are published in a dynamic report (also downloadable in PDF format) that is made available in your personal OncoSHARE™ account.

6 INDIVIDUAL SUPPORT Support is available at all times. Feel free to reach out to our scientific team at [email protected] and to our logistics team at [email protected] for any inquiries. OncoDNA Headquarters

OncoDNA S.A. 1 Rue Louis Bréguet 6041 Gosselies - Belgium www.oncodna.com